JPET Medipak's UVLI- Bags blind and protect

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 27, 2005; DOI: 10.1124/jpet.105.091306


0022-3565/06/3161-295-303$20.00
JPET 316:295-303, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.091306v1
jpet.105.091306v2
316/1/295    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by von Weymarn, L. B.
Right arrow Articles by Murphy, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by von Weymarn, L. B.
Right arrow Articles by Murphy, S. E.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CARBON MONOXIDE
*NICOTINE
*NICOTINE TARTRATE

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Inactivation of CYP2A6 and CYP2A13 during Nicotine Metabolism

Linda B. von Weymarn, Kathryn M. Brown, and Sharon E. Murphy

Department of Biochemistry, Molecular Biology, and Biophysics and The Cancer Center University of Minnesota, Minneapolis, Minnesota

Nicotine is the major addictive agent in tobacco. The primary catalyst of nicotine metabolism in humans is CYP2A6. However, the closely related enzyme CYP2A13 is a somewhat better catalyst. CYP2A13 is an extrahepatic enzyme that is an excellent catalyst of the metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone (NNK). Here we report that both CYP2A6 and CYP2A13 were inactivated during nicotine metabolism. Inactivation of both enzymes was dependent on NADPH and increased with time and concentration. Alternate substrates for CYP2A6 and CYP2A13 protected these enzymes from inactivation. Inactivation of CYP2A13 was irreversible upon extensive dialysis and seems to be mechanism-based. The KI of CYP2A13 inactivation by nicotine was 17 µM, the rate of inactivation, kinact, was 0.1 min-1, and the t1/2 was 7 min. However, the loss in enzyme activity occurred after nicotine metabolism was complete, suggesting that a secondary or possible tertiary metabolite of nicotine may be responsible. [5-3H]Nicotine metabolism by CYP2A13 was monitored by radioflow high-pressure liquid chromatography during the course of enzyme inactivation; the major product was the {Delta}1'(5')iminium ion. However, cotinine was a significant metabolite even at short reaction times. The metabolism of the nicotine {Delta}1'(5')iminium ion to cotinine did not require the addition of aldehyde oxidase. CYP2A13 catalyzed this reaction as well as further metabolism of cotinine to 5'-hydroxycotinine, trans-3'-hydroxycotinine, and N-(hydroxymethyl)-norcotinine as enzyme inactivation occurred. Studies are on-going to identify the metabolite responsible for nicotine-mediated inactivation of CYP2A13.


Received June 21, 2005; accepted September 26, 2005.

Address correspondence to: Dr. Sharon E. Murphy, The Cancer Center, University of Minnesota, Mayo Mail Code 806, 420 Delaware Street, S.E., Minneapolis, MN 55455. E-mail: murph062{at}umn.edu




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
P. J. Brown, L. L. Bedard, K. R. Reid, D. Petsikas, and T. E. Massey
Analysis of CYP2A Contributions to Metabolism of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone in Human Peripheral Lung Microsomes
Drug Metab. Dispos., November 1, 2007; 35(11): 2086 - 2094.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.